Halozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will host an Investor Conference Call on Wednesday ...
Halozyme: 'Accidental' Business Model Has Exciting Upside Opportunities In 2025
Halozyme provides subcutaneous drug delivery solutions, with several major new products recently approved. Click here to find ...
Halozyme Announces argenx's VYDURA with ENHANZE® was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy
Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx's VYVDURA (efgartigimod alfa and ...
Halozyme announces Vyvdura co-formulated with Enhanze granted MHLW approval
Halozyme announced that Argenx’s Vyvdura, which is co-formulated with Halozyme’s Enhanze drug delivery technology, was granted regulatory approval by Japan’s Ministry of Hea ...
The American Journal of Managed Care4d
FDA Approves First Subcutaneous Nivolumab Injection in Most Solid Tumors
FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.
Business Insider7d
Halozyme Says FDA Approved Bristol Myers's Opdivo Qvantig With ENHANZE For Subcutaneous Use
(RTTNews) - Halozyme Therapeutics, Inc. (HALO) Monday said that the Food and Drug Administration (FDA) has approved Bristol Myers Squibb's Opdivo Qvantig co-formulated with Halozyme's ENHANZE drug ...
Hosted on MSN21d
If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now
The company also licenses its novel drug delivery technology, ENHANZE, for subcutaneous (SC) administration of drugs. The company’s ENHANZE drug delivery technology helps in developing SC ...
FiercePharma4d
Bristol Myers celebrates 10 years of Opdivo with FDA approval for subcutaneous version
Almost exactly 10 years after the FDA’s initial FDA approval for Bristol Myers Squibb’s Opdivo as the first PD-1 inhibitor in ...
Contract Pharma7d
FDA Approves BMS’ Opdivo Qvantig with Halozyme’s ENHANZE Technology
Becomes the first subcutaneously administered PD-1 inhibitor.
Zacks.com on MSN7d
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. Featuring daily updates ...